المؤلفون: Thomas R Walters, Jen Watts, Christopher M. Adams, James H. Peace, Cynthia L. Grosskreutz, Rebecca C. Stacy, Kenneth N Sall, Yunsheng He, Ganesh Prasanna, Xiao Ni, Jing-He Yan, John J. Seaman, Muneto Mogi, Randall Kolega, Ronald Newton, Michael Wald, David Wirta, Kenneth Huttner

المصدر: American Journal of Ophthalmology. 192:113-123

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Intraocular pressure, medicine.medical_specialty, Adolescent, Maximum Tolerated Dose, genetic structures, Pyridines, Visual Acuity, Enzyme Activators, Ocular hypertension, Glaucoma, Administration, Ophthalmic, Tonometry, Ocular, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Piperidines, Ophthalmology, medicine, Humans, In patient, Adverse effect, Intraocular Pressure, Aged, No-Observed-Adverse-Effect Level, business.industry, Middle Aged, medicine.disease, eye diseases, Confidence interval, Treatment Outcome, 030104 developmental biology, Phase i ii, Tolerability, Guanylate Cyclase, 030221 ophthalmology & optometry, Pyrazoles, Female, Ocular Hypertension, sense organs, Ophthalmic Solutions, business, Glaucoma, Open-Angle

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79a3b50017ac9dbeb738006d13fa090b
https://doi.org/10.1016/j.ajo.2018.05.015